PFE Pfizer Inc. (NYSE) Pre-market 02 Feb 2026: Earnings tomorrow, guidance focus

PFE stock trades at $26.44 in US pre-market on the NYSE as investors position ahead of Pfizer Inc.’s earnings due 03 Feb 2026. Volume is active at 51,599,439 shares versus a 50-day average of 25.45 and a 200-day average of 24.60. Key metrics show EPS $1.72 and PE 15.37, with a market cap of $150.27B. This earnings spotlight focuses on guidance risk, revenue drivers like Comirnaty and Paxlovid, and what numbers could move PFE stock at the open

PFE stock pre-market snapshot

Pfizer Inc. (PFE) is quoted $26.44 in pre-market trade on the NYSE in the United States. The stock is up 1.30% on the session with an intraday range of $25.90–$26.47. Volume stands at 51,599,439 compared with an average of 63,444,259, signalling above-normal interest ahead of earnings

PFE stock earnings setup and timing

Pfizer’s earnings announcement is scheduled for 03 Feb 2026 at 08:30 EST ahead of the NYSE open. The report will likely highlight COVID-19 product revenue, Paxlovid uptake, and updated 2026 guidance. Investors should watch management commentary on margins and Biopharma launches because guidance will drive PFE stock direction

PFE stock valuation and key financials

Pfizer shows EPS $1.72, PE 15.37, and revenue per share $11.04. The dividend per share is $1.72, producing a yield near 6.50%, with a payout ratio of 0.99. Enterprise value is $210.76B and price-to-sales is 2.40, putting PFE stock in the mid-range of large-cap drugmakers on valuation

PFE stock technicals and trading signals

Technical indicators show neutral momentum for PFE stock with RSI 54.16 and MACD histogram near 0.02. Bollinger Bands middle at $25.29 imply the current price sits slightly above the 20-day mean. Traders should note ATR $0.48 and a CCI at 100.89, which flags short-term overbought conditions

PFE stock risks and near-term catalysts

Earnings guidance and product-by-product revenue will be the main catalysts for PFE stock. Risks include weaker-than-expected Comirnaty sales, Paxlovid uptake misses, and margin pressure from pricing. Positive catalysts include new label approvals, stronger biosimilar adoption, or upward revisions to 2026 guidance

PFE stock analyst view and price targets

Street consensus shows 4 Buys, 9 Holds, 1 Sell with a midpoint rating near Neutral. Reasonable near-term price targets to consider are $28.00 (bull), $24.00 (base), and $21.00 (bear). That implies upside of 5.91% to the bull case and downside of -9.23% to the base case from $26.44

Final Thoughts

Key takeaways for PFE stock ahead of earnings: first, the market prices the name at $26.44 with a PE of 15.37, leaving limited valuation stretch versus peers. Second, guidance and product revenues will be the decisive items that move shares on 03 Feb 2026. Meyka AI rates PFE with a score out of 100 at 69.95 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month level near $23.46, implying -11.27% from the current price of $26.44. Forecasts are model-based projections and not guarantees. Investors should weigh the stock’s 6.50% dividend yield, near-term earnings risk, and sector dynamics when framing position size. For live updates, use Meyka AI-powered market analysis platform and check primary sources before trading

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.